Search

Michael D. Pak

Examiner (ID: 12379, Phone: (571)272-0879 , Office: P/1646 )

Most Active Art Unit
1646
Art Unit(s)
1812, 0, 1674, 1646, 1621
Total Applications
1549
Issued Applications
720
Pending Applications
264
Abandoned Applications
571

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17113192 [patent_doc_number] => 20210293789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => RP182 COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/263409 [patent_app_country] => US [patent_app_date] => 2019-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17263409 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/263409
RP182 compositions and methods Aug 25, 2019 Issued
Array ( [id] => 17050676 [patent_doc_number] => 20210260110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => NOVEL METHODS FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS [patent_app_type] => utility [patent_app_number] => 17/269659 [patent_app_country] => US [patent_app_date] => 2019-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269659 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/269659
Methods for the production of pharmaceutical agents Aug 21, 2019 Issued
Array ( [id] => 15454457 [patent_doc_number] => 20200040053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => Ligands Modified by Circular Permutation as Agonists and Antagonists [patent_app_type] => utility [patent_app_number] => 16/519231 [patent_app_country] => US [patent_app_date] => 2019-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16519231 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/519231
Ligands Modified by Circular Permutation as Agonists and Antagonists Jul 22, 2019 Abandoned
Array ( [id] => 15175227 [patent_doc_number] => 20190358205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => FGFR GATEKEEPER MUTANT GENE AND DRUG TARGETING SAME [patent_app_type] => utility [patent_app_number] => 16/516566 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516566 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/516566
FGFR GATEKEEPER MUTANT GENE AND DRUG TARGETING SAME Jul 18, 2019 Abandoned
Array ( [id] => 15996265 [patent_doc_number] => 20200174003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => FUSION PROTEINS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 16/508021 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508021 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/508021
Fusion proteins and methods thereof Jul 9, 2019 Issued
Array ( [id] => 19013220 [patent_doc_number] => 11920138 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Fusion proteins and methods thereof [patent_app_type] => utility [patent_app_number] => 16/507977 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 108 [patent_figures_cnt] => 116 [patent_no_of_words] => 60369 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507977 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/507977
Fusion proteins and methods thereof Jul 9, 2019 Issued
Array ( [id] => 15267489 [patent_doc_number] => 20190382478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => Nucleolin Antibodies [patent_app_type] => utility [patent_app_number] => 16/454966 [patent_app_country] => US [patent_app_date] => 2019-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16454966 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/454966
Nucleolin Antibodies Jun 26, 2019 Abandoned
Array ( [id] => 14868707 [patent_doc_number] => 20190284595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => NOVEL POLYPEPTIDE AND METHOD OF PRODUCING IMP USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/425897 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16425897 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/425897
Polypeptide and method of producing IMP using the same May 28, 2019 Issued
Array ( [id] => 15254225 [patent_doc_number] => 20190375846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 16/424676 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18580 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16424676 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/424676
BINDING AGENTS May 28, 2019 Abandoned
Array ( [id] => 18545345 [patent_doc_number] => 11718685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Compositions and methods for targeting stromal cells for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/417125 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 36060 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16417125 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/417125
Compositions and methods for targeting stromal cells for the treatment of cancer May 19, 2019 Issued
Array ( [id] => 15178925 [patent_doc_number] => 20190360054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => METHOD FOR DIAGNOSIS OF METASTATIC CANCER OR TAXANE-BASED DRUG-RESISTANT CANCER BY USING LMCD1 PROTEIN AND GENE CODING THEREFOR [patent_app_type] => utility [patent_app_number] => 16/413014 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10639 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413014 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/413014
METHOD FOR DIAGNOSIS OF METASTATIC CANCER OR TAXANE-BASED DRUG-RESISTANT CANCER BY USING LMCD1 PROTEIN AND GENE CODING THEREFOR May 14, 2019 Abandoned
Array ( [id] => 16688773 [patent_doc_number] => 20210071249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => DIAGNOSTIC METHOD AND THERAPY [patent_app_type] => utility [patent_app_number] => 17/051930 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7459 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051930 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/051930
DIAGNOSTIC METHOD AND THERAPY May 6, 2019 Abandoned
Array ( [id] => 17815424 [patent_doc_number] => 11421023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Anti-GP73 monoclonal antibodies and methods of obtaining the same [patent_app_type] => utility [patent_app_number] => 16/387282 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 27 [patent_no_of_words] => 60624 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 292 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16387282 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/387282
Anti-GP73 monoclonal antibodies and methods of obtaining the same Apr 16, 2019 Issued
Array ( [id] => 15038703 [patent_doc_number] => 20190330356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/382402 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382402 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/382402
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor Apr 11, 2019 Issued
Array ( [id] => 14932951 [patent_doc_number] => 20190302113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS [patent_app_type] => utility [patent_app_number] => 16/375283 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375283 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/375283
MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS Apr 3, 2019 Abandoned
Array ( [id] => 14833411 [patent_doc_number] => 20190275106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => Anti-Angiogenic Gene Therapy Kit [patent_app_type] => utility [patent_app_number] => 16/364284 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364284 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/364284
Anti-Angiogenic Gene Therapy Kit Mar 25, 2019 Abandoned
Array ( [id] => 14929963 [patent_doc_number] => 20190300619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => GITR AGONISTS, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/358522 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358522 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/358522
GITR AGONISTS, AND METHODS OF USE THEREOF Mar 18, 2019 Abandoned
Array ( [id] => 14716183 [patent_doc_number] => 20190249155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES [patent_app_type] => utility [patent_app_number] => 16/355339 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16355339 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/355339
Fusion proteins comprising enzyme replacement therapy enzymes Mar 14, 2019 Issued
Array ( [id] => 20664841 [patent_doc_number] => 12606603 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-21 [patent_title] => IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy [patent_app_type] => utility [patent_app_number] => 16/979475 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 8679 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979475 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/979475
IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy Mar 11, 2019 Issued
Array ( [id] => 14687595 [patent_doc_number] => 20190242912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => COMPOSITION AND METHOD FOR MEASURING THALLIUM INFLUX AND EFFLUX [patent_app_type] => utility [patent_app_number] => 16/298810 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16298810 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/298810
COMPOSITION AND METHOD FOR MEASURING THALLIUM INFLUX AND EFFLUX Mar 10, 2019 Abandoned
Menu